Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
33.74
0.00 (0.00%)
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with neurological disorders
The company is dedicated to addressing unmet medical needs in this space, particularly in the areas of rare and complex conditions. By leveraging proprietary research and development capabilities, Harmony Biosciences aims to bring forth therapies that improve the quality of life for patients, while also advancing scientific understanding of neurological diseases. Their portfolio includes products targeting specific disorders, reflecting a commitment to enhancing patient outcomes through personalized and effective treatments.
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQHRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025.
HARMONY BIOSCIENCES HOLDINGS could be undervalued. NASDAQ:HRMY is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders.
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026.
